# A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

Source: https://onco.cc/trials/nct06051695/  
OnCo record `nct06051695` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of A2B694 in colorectal cancer, non-small-cell lung cancer, pancreatic ductal adenocarcinoma, ovarian cancer and mesothelioma, run by A2 Biotherapeutics Inc., now recruiting.

## Summary

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression is a phase 1/2 interventional study registered as NCT06051695 by A2 Biotherapeutics Inc., with 474 participants planned, started 2024-04-03 and due to reach its primary completion in 2028-06. Interventions recorded: A2B694 and A2B543.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06051695
- Phase: 1/2
- Setting: A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Autologous Logic-gated Tmod™ CAR T Products, in Heterozygous HLA-A*02 Adults With Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
- Sponsor: A2 Biotherapeutics Inc.
- Enrolled: 474

## Sources

- ClinicalTrials.gov NCT06051695: https://clinicaltrials.gov/study/NCT06051695

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Mesothelioma](https://onco.cc/cancers/mesothelioma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- companies: [Tempus AI](https://onco.cc/companies/tempus/)

---
JSON: https://onco.cc/api/v1/entities/nct06051695.json